Roche : FDA Okays To Expand Testing Menu For Sexually Transmitted Diseases

(RTTNews) - Roche (RHHBY.PK) said that it received a clearance from the US Food and Drug Administration to expand testing menu on cobas 6800/8800 Systems for sexually transmitted diseases. The addition of the cobas TV/MG test to the testing menu provides the flexibility to process up to four sexually transmitted infections from one patient sample.

"The launch of cobas TV/MG continues our expansion of our STI menu, giving healthcare providers and their patients greater access to more information from a single sample," said Mario Torres, Head of Roche Molecular Diagnostics.

Roche announced US Food and Drug Administration 510(k) clearance for the cobas TV/MG test for use on the cobas 6800/8800 Systems for the detection of Trichomonas vaginalis and/or Mycoplasma genitalium DNA in both symptomatic and asymptomatic patients.

Laboratories can now simultaneously process from a single patient sample a combination of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, which provides clinicians the information they need to screen and diagnose sexually transmitted infections (STIs) and improve patient care.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

RHHBY